Clinical trials: Histological Type of Neoplasm
Chronic Myeloid Leukemia, CML
Study of Olverembatinib (HQP1351) in Patients With CML-CP
Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A).
- Conditions
- Chronic Myeloid Leukemia, CML, CML, Chronic Phase
- Trial name
- POLARIS-2 (NCT06423911)
- Testing
- olverembatinib, Bosutinib
- Where
- 163 sites in United States, Australia and 14 more
- Volunteers
- 333 people
- Sponsor
- Ascentage Pharma Group Inc.
Epithelial Ovarian Cancer
Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer
The purpose of this study is to evaluate the efficacy of paclitaxel and carboplatin followed by gemcitabine and carboplatin therapy for patients with epithelial ovarian cancer.
- Trial name
- NCT00490711
- Testing
- gemcitabine, carboplatin, paclitaxel
- Where
- Slovakia
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors, NSCLC Adenocarcinoma
A Study of MGC028 in Participants With Advanced Solid Tumors
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined).
- Conditions
- Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma
- Trial name
- NCT06723236
- Testing
- MGC028
- Where
- 7 sites in United States
- Volunteers
- 124 people
- Sponsor
- MacroGenics
Squamous Cell Cancer, Squamous Cell Carcinoma
Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer
Randomized comparative trial of a 30% solution of ascorbic acid in 95% dimethylsulfoxide applied topically twice a day for 8 weeks vs 5% imiquimod cream in the treatment of biopsy proven squamous cell carcinomas of the skin in…
- Conditions
- Squamous Cell Cancer, Squamous Cell Carcinoma, Skin Cancer, Non-melanoma Skin Cancer
- Trial name
- NCT05932511
- Testing
- 30% ascorbic acid in DMSO
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Center for Biomedical Research, Inc.
Follicular Lymphoma
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy.
- Trial name
- NCT07634471
- Testing
- MK-1045, Rituximab, Rituximab biosimilar
- Where
- 35 sites in United States, Argentina and 11 more
- Volunteers
- 960 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the…
- Trial name
- AMpLify (NCT06128044)
- Testing
- CB-012
- Where
- 10 sites in United States
- Volunteers
- 12 people
- Sponsor
- Caribou Biosciences, Inc.
Advanced Melanoma
Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1
This is a phase 1b/2a study including a dose escalation part (Phase 1b) and an extension part (Phase 2a). Both parts will be open-label, multicenter study of OPM-101 combined with the anti-PD-1 pembrolizumab as per standard of…
- Trial name
- REVERT (NCT07040436)
- Testing
- OPM-101
- Volunteers
- 41 people
- Sponsor
- Oncodesign Precision Medicine
Chronic Lymphocytic Leukemia
Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia
The purpose of this study is to investigate safety and efficacy of SyB L-0501 after 2-day intravenous infusion at a dose of 100 mg/m2/day to patients with chronic lymphocytic leukemia.
- Trial name
- NCT02042911
- Testing
- SyB L-0501
- Where
- 6 sites in Japan
- Volunteers
- 10 people
- Sponsor
- SymBio Pharmaceuticals
Glioma, Astrocytoma
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
The purpose of this non-randomized, open-label, multicenter, Phase II, 2-stage design, RESCUE study is to test the hypothesis that continuous 28-day oral dosing (28/28) with dose-intense temozolomide (50 mg/m^2) for up to 12…
- Conditions
- Glioma, Astrocytoma, Oligodendroglioma, Glioblastoma
- Trial name
- NCT00392171
- Testing
- Temozolomide
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Barrett Syndrome, Barrett's Syndrome
CLE for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia
This study focuses on demonstrating the value of probe-based Confocal Laser Endomicroscopy (pCLE) in guiding endoscopic therapeutic procedures in Barrett's Esophagus (BE).
- Conditions
- Barrett Syndrome, Barrett's Syndrome, Barrett's Esophagus, Barrett Esophagus
- Trial name
- CLEAN-MARGIN (NCT01032044)
- Testing
- Standard endoscopic evaluation, pCLE guided evaluation
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 164 people
- Sponsor
- Mauna Kea Technologies
Glioblastoma, GBM
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
The purpose of this research is to test an investigational device using ultrasound along with an investigational drug to see if it is useful in treating glioblastoma following standard of care therapy surgery and chemoradiation.
- Trial name
- NCT07225621
- Testing
- 5-ALA HCl + LIDU SDT
- Where
- 11 sites in United States
- Volunteers
- 103 people
- Sponsor
- Alpheus Medical, Inc.
Gliomas
A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)
The goal of this Study is to evaluate the effectiveness and safety of Vorasidenib in Patients with Isocitrate dehydrogenase IDH1/2 mutant Grade 2 astrocytoma or oligodendroglioma, primary purposeis to evaluate the efficectiveness…
- Trial name
- VICTORIA (NCT06969352)
- Testing
- Vorasidenib
- Where
- 3 sites in China
- Volunteers
- 62 people
- Sponsor
- Servier (Tianjin) Pharmaceutical Co. LTD.
Solid Tumor, Adult
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and…
- Trial name
- NCT04130516
- Testing
- LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Linnaeus Therapeutics, Inc.
Cancer
Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer
This is a Phase 1, open-label, multi-center, first time in human study of AMP-224 in adult patients with cancer that is not responding to standard therapy.
- Trial name
- NCT01352884
- Testing
- AMP-224
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- MedImmune LLC
Malignant Pleural Mesothelioma
Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
To investigate safety of pemetrexed combined with cisplatin for chemo therapy-naive patients with malignant pleural mesothelioma
- Trial name
- NCT00386815
- Testing
- pemetrexed, cisplatin
- Where
- 7 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Melanoma, Prostate Cancer
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with…
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- IVY (NCT02009449)
- Testing
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
- Where
- 10 sites in United States
- Volunteers
- 353 people
- Sponsor
- Eli Lilly and Company
Multiple Myeloma
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Multiple myeloma (MM) is an incurable malignancy and accounts for 1 percentage (%) of all cancers and for 10% of all hematologic malignancies.
- Trial name
- NCT03525678
- Testing
- Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 221 people
- Sponsor
- GlaxoSmithKline
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies…
- Conditions
- Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL)
- Trial name
- NCT03547115
- Testing
- voruciclib monotherapy, voruciclib and venetoclax
- Where
- 12 sites in United States
- Volunteers
- 84 people
- Sponsor
- MEI Pharma, Inc.
Relapsed/Refractory Multiple Myeloma
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
The primary purpose of the phase 1 part of the study is to evaluate safety and tolerability of AMG 701 monotherapy to identify the RP2D for AMG 701 monotherapy followed by a dose-confirmation part to gather further safety data…
- Trial name
- NCT03287908
- Testing
- AMG 701, Pomalidomide, Dexamethasone
- Where
- 34 sites in United States, Australia and 4 more
- Volunteers
- 174 people
- Sponsor
- Amgen
Non-Hodgkin's Lymphoma, Autologous Transplantation
Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).
This is a long-term observational study of patients that were treated with at least 1 dose of study treatment (plerixafor or placebo) in the AMD3100-3101 protocol (NCT00103610).
- Trial name
- NCT00741325
- Testing
- granulocyte colony-stimulating factor (G-CSF), plerixafor
- Volunteers
- 178 people
- Sponsor
- Genzyme, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.